Jong-Ho Hong
Chief Executive Officer bij KUKJEON PHARMACEUTICAL CO., LTD
Vermogen: 97 M $ op 31-03-2024
Profiel
Jong-Ho Hong is currently the Chief Executive Officer at Kukjeon Pharm Co., Ltd.
and the Chief Executive Officer & Director at Kukjeon Pharmaceutical Co., Ltd.
He has a graduate degree from Sogang University and an undergraduate degree from Sungkyunkwan University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 22-04-2024 | 21 373 361 ( 43.56% ) | 97 M $ | 31-03-2024 |
Actieve functies van Jong-Ho Hong
| Bedrijven | Functie | Begin |
|---|---|---|
| KUKJEON PHARMACEUTICAL CO., LTD | Chief Executive Officer | - |
Kukjeon Pharm Co., Ltd.
 Kukjeon Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Kukjeon Pharm Co., Ltd. manufactures medicines and antibiotics. The firm’s products include celecoxib, choline alfoscerate, dibucaine, enoxolone, eperisone HCL, epinastine HCL, hinokitiol and nizatidine. The company was founded on July 26, 1995 and is headquartered in Anyang-si, South Korea. | Chief Executive Officer | - |
Opleiding van Jong-Ho Hong
| Sogang University | Graduate Degree |
| Sungkyunkwan University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Kukjeon Pharm Co., Ltd.
Kukjeon Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Kukjeon Pharm Co., Ltd. manufactures medicines and antibiotics. The firm’s products include celecoxib, choline alfoscerate, dibucaine, enoxolone, eperisone HCL, epinastine HCL, hinokitiol and nizatidine. The company was founded on July 26, 1995 and is headquartered in Anyang-si, South Korea. | Health Technology |
| Kukjeon Pharmaceutical Co., Ltd. |
